Search company, investor...
LabCorp Drug Development company logo

LabCorp Drug Development

drugdevelopment.labcorp.com

Founded Year

1997

Stage

Acq - P2P | Acquired

Valuation

$0000 

About LabCorp Drug Development

LabCorp Drug Development provides advanced drug, device, and diagnostic breakthroughs.

Headquarters Location

210 Carnegie Center

Princeton, New Jersey, 08540,

United States

609-452-8550

Missing: LabCorp Drug Development's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: LabCorp Drug Development's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing LabCorp Drug Development

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned LabCorp Drug Development in 1 CB Insights research brief, most recently on Dec 14, 2020.

Expert Collections containing LabCorp Drug Development

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

LabCorp Drug Development is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

72 items

https://www.amdm.org/members.html

LabCorp Drug Development Patents

LabCorp Drug Development has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/12/2004

4/20/2010

Catheters, Fluid dynamics, Medical equipment, Implants (medicine), Aerodynamics

Grant

Application Date

3/12/2004

Grant Date

4/20/2010

Title

Related Topics

Catheters, Fluid dynamics, Medical equipment, Implants (medicine), Aerodynamics

Status

Grant

Latest LabCorp Drug Development News

Food Safety Testing Market will worth USD 37.01 billion by 2030 : GreyViews

Jan 16, 2023

Major Players Thermo Fischer Scientific Inc., UL LLC, EMSL Analytical Inc., Microbac Laboratories, Inc., Silliker, Inc., Covance Inc., Intertek Group Plc., SGS SA, Bureau Veritas S.A., Eurofins Scientific SE, The SOCOTEC Group, International Laboratory Services, ALS Limited, AsureQuality Limited, DTS Food Laboratories, Aspirata, Symbio among other. Segmentation Analysis The Microbiological Testing  segment is expected to be the fastest-growing segment in 2022. The test segment is Chemical & Nutritional testing, Microbiological Testing, Allergen Testing, Residues & Contamination Testing, Genetically modified Organism Testing and Other. The Microbiological Testing segment will witness the highest growth rate during the forecast period. As it assists in the identification of microorganisms in food items employing chemical, biological, molecular, and biochemical procedures, offering remarkably accurate results regarding their composition, the market is predicted to expand. Microbiological testing on edible products can identify indicator microorganisms such faecal contamination, heat-resistant bacteria, and acid-resistant microorganisms. These tests can also identify industrial microbes such Bifidobacteria, Lactobacillus casei, and Lactobacillus rhamnosus. The Meat, Poultry & Seafood Products segment is expected to be the fastest-growing segment in 2022. The application egment is Cereals & Grains, Processed Food, Meat, Poultry & Seafood Products, Beverages and Dairy & Dairy Products. The Meat, Poultry & Seafood Products  segment is expected to witness the highest growth rate during the forecast period. Due to increased global consumption of meat and meat products as well as the significant illness risk associated with red meat, the category is expected to grow during the forecast period. Regional Analysis            The regional analysis provides a detailed perception of the key regions and the countries. Some of the key countries analyzed for the food safety testing include the US, Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, Brazil, Peru, UAE, South Africa, and Saudi Arabia. The Europe region witnessed a major share. The food and beverage industry contributes significantly to Europe's economy. The industry is still showing signs of being robust, adaptable, and stable. Market growth is predicted to be fueled by product manufacturers' increased focus on maintaining the safety of food products over the course of the forecast period. The largest market share in Europe for food safety testing systems in 2018 was held by Germany, and it is projected that this trend will continue over the forecast period. The market is predicted to see a growth in demand for microbiological testing, followed by chemical & residues contamination testing, in order to prevent foodborne illness outbreaks and avoid consuming drug residues and heavy metals that are harmful for human consumption. Country Analysis Germany Germany's Food Safety Testing market size was valued at USD 4.78 billion in 2022 and is expected to reach USD 7.52 billion by 2030, at a CAGR of 7.5% from 2023 to 2030. The market is predicted to see a growth in demand for microbiological testing, followed by chemical & residues contamination testing, in order to prevent foodborne illness outbreaks and avoid consuming drug residues and heavy metals that are harmful for human consumption. China China’s Food Safety Testing market size was valued at USD 4.27 billion in 2022 and is expected to reach USD 6.36 billion by 2030, at a CAGR of 7.9% from 2023 to 2030. Resulting from the massive growth of the food business in emerging countries and the rising demand for stronger food safety regulations to address a number of food scandals and contamination issues. India India's Food Safety Testing market size was valued at USD 5.23 billion in 2022 and is expected to reach USD 8.29 billion by 2030, at a CAGR of 7.3% from 2023 to 2030 Unknown pathogen activity is a serious issue in India that causes food contamination. Children are now more frequently affected by foodborne illness outbreaks around the country. Farmers in India utilise a range of pesticides and fertilisers, the use of which is badly regulated, to meet the expanding demand. As a result, the final product frequently include traces of both the veterinary drugs or antibiotics used in animal farming as well as the agrochemicals used to grow the crop. The residues therefore enter the food chain. To avoid consuming harmful residues in food products, it is essential to test food for safety. Covid-19 Impact Covid-19 had a major impact on almost all industries, such as electronics, semiconductors, manufacturing, automobile, etc. However, several companies operating in the technology sector have seen increased revenue due to significant changes in consumer preferences toward technological services. In addition, the pandemic has led to significant growth in technology across developing and developed countries. Furthermore, the growth of the food safety testing market is mainly driven by the rise in demand. Buy Now Full Report @  https://greyviews.com/checkout/371/single_user_license Contact Us

LabCorp Drug Development Frequently Asked Questions (FAQ)

  • When was LabCorp Drug Development founded?

    LabCorp Drug Development was founded in 1997.

  • Where is LabCorp Drug Development's headquarters?

    LabCorp Drug Development's headquarters is located at 210 Carnegie Center, Princeton.

  • What is LabCorp Drug Development's latest funding round?

    LabCorp Drug Development's latest funding round is Acq - P2P.

  • Who are the investors of LabCorp Drug Development?

    Investors of LabCorp Drug Development include LabCorp.

  • Who are LabCorp Drug Development's competitors?

    Competitors of LabCorp Drug Development include LunaPBC and 3 more.

Compare LabCorp Drug Development to Competitors

P
Precision Medicine Group

Precision Medicine Group is a specialized services company supporting next generation approaches to drug development and commercialization. Precision provides an integrated infrastructure that supports pharmaceutical and life sciences companies as they develop new products in the age of precision medicine.

P
PrognomIQ

PrognomIQ is a healthcare company pursuing the development and commercialization of multi-omics human tests for cancer and other complex diseases.

Genome Medical Logo
Genome Medical

Genome Medical is a national telegenomics technology and services company bringing genomic medicine to everyday care. Through its nationwide network of genetic specialists and efficient genomic care delivery platform, it provides virtual genetic care for individuals and their families to improve health and well-being. The company also helps healthcare providers and their patients navigate the rapidly expanding field of genetics and utilize test results to understand the risk for disease, accelerate disease diagnosis, make informed treatment decisions and lower the cost of care.

Fabric Genomics Logo
Fabric Genomics

Fabric Genomics, formerly Omicia, is a computational genomics company offering end-to-end genomic data analysis, annotation, curation, classification and reporting solutions to clinical labs, hospital labs, country sequencing programs and life science companies. Fabric Genomics' analytic capabilities begin with raw data analysis and include the delivery of rapid, comprehensive insights for high throughout panels, exomes, and whole genomes. The company can process any NGS file input (e.g. FASTQ, BAM or VCF) providing alignment, variant calling, annotation, guideline-driven variant classification, variant interpretation and clinical reporting for both hereditary disease and oncology. Fabric Genomics was founded by scientists and industry pioneers in bioinformatics, large-scale genomics and molecular diagnostics, and is headquartered in Oakland, California with satellite offices in London, Seattle, Salt Lake City and Boston. By accelerating access to insights related to the cause of genetic diseases, Fabric Genomics is leading the way in precision healthcare.

Embark Veterinary Logo
Embark Veterinary

Embark Veterinary has developed a comprehensive dog DNA test that tracks over 200,000 genetic markers, offering ancestry analysis as well as key insights into genetic disease risk and heritable traits.

Congenica Logo
Congenica

Congenica provides clinical genome analysis technology. Congenica has developed the Sapientia technology platform to analyze genome-scale DNA data, producing comprehensive diagnostic reports that facilitate clinical decision-making and inform R&D.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.